Is that why TCR2 Therapeutics Inc. (Nasdaq: TCRR) shares soared in the late hours on Friday?

TCR2 Therapeutics Inc. (Nasdaq: TCRR), the stock surged higher in the after-market session as it was up 33.36% to $43.6. As a clinical-stage immunotherapy company with a pipeline of novel T cell-based therapies for cancer patients, we revealed today positive interim results from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial.

In the first eight patients treated on the study, three PRs have been achieved based on RECIST 1.1 criteria by the November 24, 2020 data cutoff, with our very first patient had achieved a confirmed PR up to month six.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Furthermore, the first patient-administered at a higher dose of gave-cel (1×108/m2) without lymphodepletion had a stable condition within two months without any noticeable toxicity, enabling patients to resume therapy with the addition of lymphodepletion at that dose.

The toxicology profile remains manageable, with only two patients reporting gavo-cel-related non-hematological grade >2 toxicity to date and no indication of neurotoxicity or on-target, off-tumor side effects. In all patients, translational data demonstrated the expansion of TRuC-T cells and the induction of cytokines.

Most Popular

Related posts